An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 05 Mar 2018
At a glance
- Drugs Lapatinib (Primary) ; Capecitabine; Docetaxel; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Letrozole; Oxaliplatin; Paclitaxel; Trastuzumab
- Indications Breast cancer; Solid tumours
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; Novartis
- 31 Oct 2016 Status changed from active, no longer recruiting to completed.
- 27 Jul 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2016.
- 27 Jul 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Dec 2016.